A filter for purifying blood (1, 100), comprising a container body (2, 102) in which there are: —an intake port (3, 103) for an incoming blood stream (4, 104), —a first discharge port (5, 105) for an outgoing blood stream (6, 106), and —a second discharge port (7, 107) for a purified plasma stream (8, 108); the container body (2, 102) comprises first filtering means (9, 109) adapted to separate a stream of plasma to be purified (10, 100) from the incoming blood stream (4, 104), and second filtering means (11, 111) adapted to purify the stream of plasma to be purified (10, 110) to obtain the purified plasma stream (8, 108).

A method for extracorporeal treatment of a body fluid of a patient suffering from sepsis, in an extracorporeal flow line, comprising removing at least one harmful substance from the body fluid of the patient. In a first injection step, a first mixture containing functionalized magnetic particles bound to at least a first binding agent at least directed against a first type of target molecules contained in the body fluid is added to the extracorporeal flow line comprising a sample of the body fluid extracted from a patient and containing at least the first type of target molecules. The first mixture is injected in a therapeutically effective dose necessary to reduce a concentration of the target molecules of at least the first type in the body fluid sample of the patient, followed by a mixing step and a separation step for reduction of the target molecule concentration.

The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

The invention resides in an apparatus for treatment of a substance. The apparatus has a substance tube for enabling a substance to be treated to pass in to the substance tube via the substance-inlet and out of the substance tube through the substance-outlet. The apparatus also has a cleaning chamber, wherein the substance tube is configured in fluid communication with the cleaning chamber to enable a substance to diffuse the permeable membrane between the substance tube and the cleaning chamber such that a substance can be substantially cleaned by a cleaner, the substance comprising blood or plasma and the cleaner comprising a cell culture. The substance tube is removably connectable with the cleaning chamber for inter-changeability or serviceability. The apparatus can further comprise a support compartment configured to connect to, or enclosing, the cleaning chamber, which functions to carry a fluid to substantially maintain the functionality of the cleaner.

This invention discloses methods for reducing physiologic molecules in abnormal levels and/or exogenous toxins in blood from blood by way of an extracorporeal circuit comprising a hollow-fiber filter module and polymer sorbent in combination.

A dialysis device comprises at least a first membrane and a second membrane, wherein a first chamber formed by the first membrane is configured to receive a first fluid; a second chamber formed by the second membrane is configured to receive a second fluid; a third chamber formed in between a housing, the first membrane and the second membrane is configured to receive a third fluid; the first fluid flowing through the first membrane can be indirectly communicated with the second fluid flowing through the second membrane via the third fluid. A dialysis system, use of the dialysis device, a method for establishing the dialysis system, a method for filling and/or priming the dialysis system and a method for removing air are further disclosed. The dialysis device and the dialysis system are suitable for viscous biological dialysis fluid and no direct flow occurs between the patient and the dialysis fluid.

This invention discloses methods for reducing physiologic molecules in abnormal levels and/or exogenous toxins in blood from blood by way of an extracorporeal circuit comprising a hollow-fiber filter module and polymer sorbent in combination.

Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines.

A method for filtering blood is disclosed that in one embodiment includes the steps of depositing unfiltered blood along at least one side of a semi-permeable surface having multiple pores, depositing target tissue along at least an opposing side of the semi-permeable surface, and permitting the unfiltered blood to flow at least partially along the semi-permeable surface to filter the unfiltered blood. Embodiments of the invention can remove self-directed autoantibodies from the blood while reducing the complications of conventional treatments such as plasmaphoresis, and return the patient's own blood cells and its plasma components, less the disease-causing self-directed antibodies. A blood filter and a blood bag are also disclosed.

Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.